BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
BridgeBio Oncology Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$2.85+0.03 (+1.06%)
Close on Oct 19, 2026
- Market cap
- $228.15M
- P/E (TTM)
- –
- Dividend yield
- –
BridgeBio Oncology Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Market Cap | $228.50M | $166.30M |
| Enterprise Value | -$115.60M | $88.19M |
| PB Ratio | 0.71 | 2.03 |
| P/TBV Ratio | 0.71 | 2.29 |
Income (trailing twelve months)
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$198.96M | -$21.40M |
| Net Income | -$182.11M | -$22.46M |
| EBITDA | -$198.96M | -$16.91M |
Returns
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -381.9% | -53.2% |
| Return on Assets (ROA) | -63.4% | -40.9% |
| Return on Capital Employed (ROCE) | -61.2% | -38.1% |
Balance sheet
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $344.10M | $61.43M |
| Net Cash (Debt) | $344.10M | $15.35M |
| Net Cash Per Share | $4.29 | $0.66 |
| Equity (Book Value) | $323.11M | $49.09M |
| Book Value Per Share | $4.03 | $1.37 |
| Tangible Book Value | $323.11M | $23.52M |
| Working Capital | $190.74M | $76.81M |
Financial position
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.69 | 3.34 |
| Quick Ratio | 6.66 | 2.44 |
Cash flow (trailing twelve months)
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$151.28M | -$12.35M |
| Capital Expenditures | -$284.00K | -$1.08M |
| Free Cash Flow | -$151.56M | -$20.22M |
| FCF Per Share | -$1.89 | -$0.42 |
Efficiency
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.98M | -$703.34K |
| Employee Count | 92 | 74 |
Dividends and yields
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -79.7% | -23.3% |
| FCF Yield | -66.3% | -8.72% |
Shares
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 80,174,300 | 58,127,000 |
| Shares Change (QoQ) | 0.03% | 0.54% |
| Float | 42,406,700 | 49,136,700 |
| Shares Held by Insiders | 47.1% | 11.6% |
| Shares Held by Institutions | 73.8% | 59.4% |
Scores
| Measure | BridgeBio Oncology Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.27 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from BridgeBio Oncology Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.